Drug or treatment

Odronextamab clinical trials

• 8Clinical trials
• 24Countries

Newest trials

All recruiting trials (8)

• Odronextamab for previously untreated low-tumor-volume advanced follicular lymphoma

  This study will try odronextamab, an antibody immunotherapy, in adults with previously untreated low-tumor-volume advanced follicular lymphoma to see if it is safe and effective.

  Recruiting Phase 2 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07128641

• Odronextamab with CAR T‑cell therapy for relapsed or refractory diffuse large B‑cell lymphoma

  This trial tests whether giving odronextamab before or after CAR T‑cell therapy helps adults with diffuse large B‑cell lymphoma that has relapsed or not responded to prior treatments.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06854159

• Odronextamab as bridging therapy for relapsed or refractory large B‑cell lymphoma before CAR‑T

  This trial tests whether giving odronextamab before CAR‑T cell therapy can keep disease under control in adults with relapsed or refractory large B‑cell lymphomas.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT06784726

• Zanubrutinib with odronextamab for Richter's transformation

  This phase I test will see if combining zanubrutinib with odronextamab helps adults whose chronic lymphocytic leukemia has transformed into aggressive lymphoma (Richter's transformation).

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06735664

• Testing a new drug combination for relapsed or refractory follicular and marginal zone lymphoma

  This study is testing a new combination of drugs to see if it can help adults with relapsed or hard-to-treat follicular or marginal zone lymphoma feel better compared to standard treatment.

  Recruiting at 167 sites Phase 3 Regeneron Pharmaceuticals · Los Angeles, California and 170 other locations · NCT06149286

• Odronextamab with chemo vs rituximab with chemo in untreated DLBCL

  A new treatment approach using odronextamab plus chemotherapy is being tested to see if it works better and is as safe as rituximab plus chemotherapy for adults with newly diagnosed diffuse large B-cell lymphoma.

  Recruiting at 182 sites Phase 3 Regeneron Pharmaceuticals · Scottsdale, Arizona and 194 other locations · NCT06091865

• Testing a new drug called odronextamab for treating follicular lymphoma

  This study is testing a new drug called odronextamab to see if it can safely and effectively treat people with follicular lymphoma who haven't received treatment before.

  Recruiting at 145 sites Phase 3 Regeneron Pharmaceuticals · Tucson, Arizona and 189 other locations · NCT06091254

• Testing a new drug combination for aggressive B-cell lymphoma

  This study is testing a new combination of two experimental drugs to see if they can help adults with aggressive B-cell lymphoma that hasn’t responded to other treatments.

  Recruiting at 20 sites Phase 1 Regeneron Pharmaceuticals · Duarte, California and 19 other locations · NCT05685173

Quick answers

How many clinical trials of Odronextamab are recruiting right now?

8, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 24 countries. The most sites are in United States (8 trials), France (4 trials), Spain (4 trials), United Kingdom (4 trials), Australia (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 3: 3, Phase 1: 2. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →